» Articles » PMID: 38791384

In Silico Search for Drug Candidates Targeting the PAX8-PPARγ Fusion Protein in Thyroid Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 May 25
PMID 38791384
Authors
Affiliations
Soon will be listed here.
Abstract

The PAX8/PPARγ rearrangement, producing the PAX8-PPARγ fusion protein (PPFP), is thought to play an essential role in the oncogenesis of thyroid follicular tumors. To identify PPFP-targeted drug candidates and establish an early standard of care for thyroid tumors, we performed ensemble-docking-based compound screening. Specifically, we investigated the pocket structure that should be adopted to search for a promising ligand compound for the PPFP; the position of the ligand-binding pocket on the PPARγ side of the PPFP is similar to that of PPARγ; however, the shape is slightly different between them due to environmental factors. We developed a method for selecting a PPFP structure with a relevant pocket and high prediction accuracy for ligand binding. This method was validated using PPARγ, whose structure and activity values are known for many compounds. Then, we performed docking calculations to the PPFP for 97 drug or drug-like compounds registered in the DrugBank database with a thiazolidine backbone, which is one of the characteristics of ligands that bind well to PPARγ. Furthermore, the binding affinities of promising ligand candidates were estimated more reliably using the molecular mechanics Poisson-Boltzmann surface area method. Thus, we propose promising drug candidates for the PPFP with a thiazolidine backbone.

Citing Articles

Location based BRAF V600E mutation status and dimension patterns of sporadic thyroid nodules: a population-based study.

Tang H, Guo D, Yang B, Huang S BMC Cancer. 2025; 25(1):406.

PMID: 40050757 PMC: 11884127. DOI: 10.1186/s12885-025-13776-y.

References
1.
Tian S, Sun H, Pan P, Li D, Zhen X, Li Y . Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility. J Chem Inf Model. 2014; 54(10):2664-79. DOI: 10.1021/ci500414b. View

2.
Dobson M, Diallo-Krou E, Grachtchouk V, Yu J, Colby L, Wilkinson J . Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology. 2011; 152(11):4455-65. PMC: 3199014. DOI: 10.1210/en.2011-1178. View

3.
Lipinski C . Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2014; 1(4):337-41. DOI: 10.1016/j.ddtec.2004.11.007. View

4.
Vuttariello E, Biffali E, Pannone R, Capiluongo A, Monaco M, Sica V . Rapid methods to create a positive control and identify the rearrangement in FNA thyroid samples by molecular biology. Oncotarget. 2018; 9(27):19255-19262. PMC: 5922393. DOI: 10.18632/oncotarget.24995. View

5.
Kumar H, Tang L, Yang C, Kim P . FusionPDB: a knowledgebase of human fusion proteins. Nucleic Acids Res. 2023; 52(D1):D1289-D1304. PMC: 10767906. DOI: 10.1093/nar/gkad920. View